KẾT QUẢ ĐIỀU TRỊ SUY SINH DỤC BẰNG LIỆU PHÁP THAY THẾ TESTOSTERONE Ở NAM GIỚI MẮC ĐÁI THÁO ĐƯỜNG TÍP 2 TẠI BỆNH VIỆN ĐA KHOA THÀNH PHỐ CẦN THƠ

Abstract

Background: Insulin resistance in men with type 2 diabetes mellitus (T2DM) is strongly correlated with low circulating testosterone levels. Although testosterone replacement therapy (TRT) has demonstrated clinical efficacy in this population, evidence from Viet Nam remains scarce. Objectives: To assess short-term therapeutic outcomes of TRT in hypogonadal men with T2DM after 3 months of treatment. Materials and methods: An uncontrolled interventional study was conducted in 42 hypogonadal men with T2DM treated at Can Tho City General Hospital between July 2024 and June 2025. Results: Mean body weight decreased significantly from 62.79 kg to 62.24 kg (p < 0.05). The prevalence of obesity declined to 28.6%; however, the overall proportion of overweight plus obese individuals did not change significantly (p > 0.05). Mean BMI showed a significant reduction (p < 0.05). Most hypogonadal symptoms assessed by the ADAM questionnaire improved, with a significant downward trend in symptom prevalence following TRT (p < 0.05). Fatigue, decreased energy, depressed mood or irritability, and diminished work capacity exhibited numerical reductions that did not reach statistical significance (p > 0.05). The mean total ADAM score declined from 7.12 ± 1.90 at baseline to 5.83 ± 2.17 post-treatment (p < 0.001). Only one patient experienced a mild injection-site reaction; no other adverse effects were observed. Conclusion:  Three-month testosterone replacement therapy yielded significant symptomatic improvement and was well tolerated in hypogonadal men with T2DM.